Susquehanna International Group’s Intersect ENT, Inc XENT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q1 | – | Sell |
-31,500
| Closed | -$860K | – | 14493 |
|
|
2021
Q4 | $860K | Sell |
31,500
-15,500
| -33% | -$420K | ﹤0.01% | 7696 |
|
|
2021
Q3 | $1.28M | Buy |
47,000
+25,600
| +120% | +$633K | ﹤0.01% | 6920 |
|
|
2021
Q2 | $366K | Buy |
21,400
+6,000
| +39% | +$112K | ﹤0.01% | 10346 |
|
|
2021
Q1 | $322K | Buy |
+15,400
| New | +$355K | ﹤0.01% | 10457 |
|
|
2019
Q3 | – | Sell |
-47,300
| Closed | -$1.08M | – | 11087 |
|
|
2019
Q2 | $1.08M | Buy |
47,300
+23,200
| +96% | +$626K | ﹤0.01% | 5479 |
|
|
2019
Q1 | $775K | Buy |
24,100
+8,300
| +53% | +$257K | ﹤0.01% | 5497 |
|
|
2018
Q4 | $445K | Sell |
15,800
-63,200
| -80% | -$1.85M | ﹤0.01% | 6256 |
|
|
2018
Q3 | $2.27M | Buy |
+79,000
| New | +$2.37M | ﹤0.01% | 3788 |
|
|
2018
Q1 | – | Sell |
-8,500
| Closed | -$275K | – | 10489 |
|
|
2017
Q4 | $275K | Buy |
8,500
+200
| +2% | +$6K | ﹤0.01% | 7739 |
|
|
2017
Q3 | $259K | Sell |
8,300
-2,400
| -22% | -$71K | ﹤0.01% | 7630 |
|
|
2017
Q2 | $299K | Sell |
10,700
-2,000
| -16% | -$45.3K | ﹤0.01% | 7606 |
|
|
2017
Q1 | $218K | Buy |
+12,700
| New | +$178K | ﹤0.01% | 7878 |
|
Susquehanna International Group's XENT Position: Q2 2022 in Review
Susquehanna International Group sold out of Intersect ENT, Inc (XENT) in Q2 2022, closing a stake of 30,917 shares — an estimated $866K sold.
Susquehanna International Group first reported a position in XENT in Q4 2015 and held it in 16 quarters. The position peaked at $2.28M in Q2 2017. 0 funds tracked by Wall St. Rank hold XENT as of Q2 2022.
- Susquehanna International Group reported no remaining Intersect ENT, Inc position as of Q2 2022 after selling out during the quarter.
- Susquehanna International Group sold 30,917 Intersect ENT, Inc shares in Q2 2022, an estimated $866K.
- Susquehanna International Group first reported a position in Intersect ENT, Inc in Q4 2015 and held it in 16 quarters.
- Susquehanna International Group's Intersect ENT, Inc position peaked at $2.28M in Q2 2017.
- 0 funds tracked by Wall St. Rank held Intersect ENT, Inc as of Q2 2022.
Based on Susquehanna International Group's 13F filing for Q2 2022, filed 15 Aug 2022.